MEDMIRA LABORATORIES INC

MedMira Laboratories Inc. specializes in the development and manufacturing of in-vitro diagnostic substances, including reagents, test kits, and diagnostic sets used in clinical and point-of-care settings. Their technical expertise lies in the design, validation, and production of precision diagnostic assays that support rapid, accurate detection of biomarkers and infectious agents. The company demonstrates proficiency in regulatory-compliant manufacturing processes for diagnostic reagents, ensuring consistency, sensitivity, and specificity required for federal healthcare applications. Their focus on diagnostic substance manufacturing reflects a niche specialization in translating laboratory-developed tests into scalable, reliable commercial products for clinical use. The contractor has delivered diagnostic solutions to the Department of Veterans Affairs, indicating a proven ability to meet the operational needs of large-scale federal healthcare systems. Their work supports VA’s mission to provide timely, accurate diagnostic testing for veteran populations, likely contributing to infectious disease screening, chronic condition monitoring, and point-of-care diagnostics in VA medical facilities. This relationship suggests a track record of fulfilling stringent federal procurement standards for medical diagnostics. MedMira’s primary industry focus is in in-vitro diagnostic substance manufacturing, a segment critical to clinical laboratories, hospital systems, and public health infrastructure. The company positions itself as a specialized supplier of proprietary diagnostic components rather than end-user devices, serving as a key enabler for diagnostic instrument manufacturers and healthcare providers requiring validated, high-performance reagents. Their market niche emphasizes quality-controlled, small-batch production tailored to clinical testing workflows. MedMira Laboratories Inc. is a small business structured as a 2L entity, headquartered in Halifax, Nova Scotia. While no federal certifications are currently listed, their ability to secure a federal contract for diagnostic substances indicates adherence to applicable quality and regulatory frameworks, including those governing medical device and reagent manufacturing under U.S. federal procurement standards. Their geographic presence supports North American supply chains with a focus on precision diagnostic manufacturing for government health programs.